<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03934229</url>
  </required_header>
  <id_info>
    <org_study_id>2018-A03140-55</org_study_id>
    <nct_id>NCT03934229</nct_id>
  </id_info>
  <brief_title>The Effect of the Probiotic Bifidobacterium Animalis Ssp. Lactis 420 (B420) on Body Fat Mass in Overweight and Obese Individuals Following Healthy Lifestyle Intervention</brief_title>
  <acronym>QLSlimCapHL</acronym>
  <official_title>The Effect of the Probiotic Bifidobacterium Animalis Ssp. Lactis 420 (B420) on Body Fat Mass in Overweight and Obese Individuals Following Healthy Lifestyle Intervention: A Randomized, Double-blind, Placebo-controlled, Multi-center Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Danisco France SAS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eurofins Optimed</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Danisco France SAS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, double-blind, placebo-controlled, multi-center, parallel group study on&#xD;
      overweight and obese individuals following healthy lifestyle consisting of calorie-reduced&#xD;
      diet (20% calorie restriction) and increase in daily activity (1000 steps more per day once&#xD;
      compared to the baseline steps)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 22, 2019</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total body fat mass relative change</measure>
    <time_frame>Change from baseline at 6 months</time_frame>
    <description>Difference in total body fat mass relative change from baseline (Visit 2) to 6 months of product intake (Visit 5) between the active vs. placebo group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Trunk fat mass change</measure>
    <time_frame>Change from baseline at 2 months, 4 months and 6 months</time_frame>
    <description>Change in trunk fat mass from baseline (Visit 2) to 2 months (Visit 3), 4 months (Visit 4) and 6 months (Visit 5) (absolute and relative)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist circumference change</measure>
    <time_frame>Change from baseline (Visit 2) to 2 months (Visit 3), 4 months (Visit 4) and 6 months (Visit 5)</time_frame>
    <description>Change in waist circumference from baseline (Visit 2) to 2 months (Visit 3), 4 months (Visit 4) and 6 months (Visit 5) (absolute and relative)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Android fat mass change</measure>
    <time_frame>Change from baseline (Visit 2) to 2 months (Visit 3), 4 months (Visit 4) and 6 months (Visit 5)</time_frame>
    <description>Change in android fat mass from baseline (Visit 2) to 2 months (Visit 3), 4 months (Visit 4) and 6 months (Visit 5) (absolute and relative)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lean body mass change</measure>
    <time_frame>Change from baseline (Visit 2) to 2 months (Visit 3), 4 months (Visit 4) and 6 months (Visit 5)</time_frame>
    <description>Change in lean body mass from baseline (Visit 2) to 2 months (Visit 3), 4 months (Visit 4) and 6 months (Visit 5) (absolute and relative)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Energy intake change</measure>
    <time_frame>Change from baseline at 6 months</time_frame>
    <description>Change in energy intake from baseline (Visit 2) to 6 months (Visit 5)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fat mass change in individual body regions</measure>
    <time_frame>Change from baseline (Visit 2) to 2 months (Visit 3), 4 months (Visit 4) and 6 months (Visit 5)</time_frame>
    <description>Change in fat mass in other individual body regions from baseline (Visit 2) to 2 months (Visit 3), 4 months (Visit 4) and 6 months (Visit 5) (absolute and relative)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total fat mass absolute change</measure>
    <time_frame>Change from baseline (Visit 2) to 2 months (Visit 3), 4 months (Visit 4) and 6 months (Visit 5)</time_frame>
    <description>Change in total body fat mass absolute change from baseline (Visit 2) to 2 months (Visit 3), 4 months (Visit 4) and 6 months (Visit 5)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight change</measure>
    <time_frame>Change from baseline (Visit 2) to 2 months (Visit 3), 4 months (Visit 4) and 6 months (Visit 5)</time_frame>
    <description>Change in body weight from baseline (Visit 2) to 2 months (Visit 3), 4 months (Visit 4) and 6 months (Visit 5) (absolute and relative)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BMI change</measure>
    <time_frame>Change from baseline at 6 months</time_frame>
    <description>Change in BMI from baseline (Visit 2) to 6 months (Visit 5) (absolute and relative)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hip circumference change</measure>
    <time_frame>Change from baseline (Visit 2) to 2 months (Visit 3), 4 months (Visit 4) and 6 months (Visit 5)</time_frame>
    <description>Change in hip circumference from baseline (Visit 2) to, 2 months (Visit 3), 4 months (Visit 4) and 6 months (Visit 5) (absolute and relative)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total fat mass relative change</measure>
    <time_frame>Change from baseline (Visit 2) to 2 months (Visit 3), and 4 months (Visit 4)</time_frame>
    <description>Change in total body fat mass relative change from baseline (Visit 2) to 2 months (Visit 3), and 4 months (Visit 4)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Food intake change</measure>
    <time_frame>Change from baseline (Visit 2) to 2 months (Visit 3), 4 months (Visit 4) and 6 months (Visit 5)</time_frame>
    <description>Change in food intake from baseline (Visit 2) to 2 months (Visit 3), 4 months (Visit 4) and 6 months (Visit 5)</description>
  </other_outcome>
  <other_outcome>
    <measure>Physical activity change</measure>
    <time_frame>Change from baseline at 6 months</time_frame>
    <description>Change in physical activity (IPAQ) from baseline (Visit 2) to 6 months (Visit 5)</description>
  </other_outcome>
  <other_outcome>
    <measure>Daily activity change</measure>
    <time_frame>Change from baseline (Visit 2) to 2 months (Visit 3), 4 months (Visit 4) and 6 months (Visit 5)</time_frame>
    <description>Change in daily activity (steps, pedometer/accelerometer) from baseline (Visit 2) to 2 months (Visit 3), 4 months (Visit 4) and 6 months (Visit 5)</description>
  </other_outcome>
  <other_outcome>
    <measure>Fasting glucose levels change</measure>
    <time_frame>Change from baseline at 6 months</time_frame>
    <description>Change in fasting glucose levels from baseline (Visit 2) to 6 months (Visit 5)</description>
  </other_outcome>
  <other_outcome>
    <measure>Fasting insulin levels change</measure>
    <time_frame>Change from baseline at 6 months</time_frame>
    <description>Change in fasting insulin levels from baseline (Visit 2) to 6 months (Visit 5)</description>
  </other_outcome>
  <other_outcome>
    <measure>Insulin resistance change</measure>
    <time_frame>Change from baseline at 6 months</time_frame>
    <description>Change in insulin resistance from baseline (Visit 2) to 6 months (Visit 5)</description>
  </other_outcome>
  <other_outcome>
    <measure>HbA1c change</measure>
    <time_frame>Change from baseline at 6 months</time_frame>
    <description>Change in glycated hemoglobin HbA1c from baseline (Visit 2) to 6 months (Visit 5)</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood lipids change</measure>
    <time_frame>Change from baseline at 6 months</time_frame>
    <description>Change in blood lipids from baseline (Visit 2) to 6 months (Visit 5)</description>
  </other_outcome>
  <other_outcome>
    <measure>Inflammation markers change</measure>
    <time_frame>Change from baseline at 6 months</time_frame>
    <description>Change in inflammation markers, as specified in Section 4.2.8, from baseline (Visit 2) to 6 months (Visit 5)</description>
  </other_outcome>
  <other_outcome>
    <measure>Circulating zonulin change</measure>
    <time_frame>Change from baseline at 6 months</time_frame>
    <description>Change in circulating zonulin from baseline (Visit 2) to 6 months (Visit 5)</description>
  </other_outcome>
  <other_outcome>
    <measure>Barrier function and endotoxemia markers change</measure>
    <time_frame>Change from baseline at 6 months</time_frame>
    <description>Change in markers of gut barrier function and endotoxemia, as specified in Section 4.2.8, from baseline (Visit 2) to 6 months (Visit 5)</description>
  </other_outcome>
  <other_outcome>
    <measure>Fecal microbiota change</measure>
    <time_frame>Change from baseline at 6 months</time_frame>
    <description>Change in fecal microbiota from baseline (Visit 2) to 6 months (Visit 5)</description>
  </other_outcome>
  <other_outcome>
    <measure>Fecal metabolites change</measure>
    <time_frame>Change from baseline at 6 months</time_frame>
    <description>Change in fecal metabolites from baseline (Visit 2) to 6 months (Visit 5)</description>
  </other_outcome>
  <other_outcome>
    <measure>Adipose tissue biomarkers change</measure>
    <time_frame>Change from baseline at 6 months</time_frame>
    <description>Change in adipose tissue biomarkers, as specified in Section 4.2.8, from baseline (Visit 2) to 6 months (Visit 5)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">418</enrollment>
  <condition>Overweight</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Group Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bifidobacterium animalis ssp. lactis 420 at 1*10^10 colony forming units (CFU) per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Daily intake of study product</intervention_name>
    <description>Daily intake of Bifidobacterium animalis ssp. lactis 420 or placebo for a 6-month period</description>
    <arm_group_label>Group Active</arm_group_label>
    <arm_group_label>Group Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Voluntary, written, signed, informed consent to participate in the study&#xD;
&#xD;
          2. Male or female, age between 20 to 65 (inclusive)&#xD;
&#xD;
          3. BMI between 28.0 and 34.9 (inclusive), of which 1:1 overweight (28.0-29.9):obese&#xD;
             (30-34.9)&#xD;
&#xD;
          4. Waist circumference for men of &gt; 102 cm or for women of &gt; 88 cm&#xD;
&#xD;
          5. Agreement to comply with the protocol and study restrictions&#xD;
&#xD;
          6. Access to Internet in addition to willingness and ability to use web-based&#xD;
             questionnaires&#xD;
&#xD;
          7. Available for all study visits&#xD;
&#xD;
          8. Females of child-bearing potential required to provide a negative urine pregnancy test&#xD;
             and agree to use a medically-approved method of birth control, eg. all of the&#xD;
             following are approved: birth control pill, patch, shot, vaginal ring, mini pill,&#xD;
             long-acting reversible contraception (LARC) meaning hormonal intrauterine device,&#xD;
             nonhormonal intrauterine device with copper, subdermal contraceptive implant, condoms,&#xD;
             cervical cap, diaphragm.&#xD;
&#xD;
          9. Covered by Health Insurance System and / or in compliance with the recommendations of&#xD;
             National Law in force relating to biomedical research.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Diagnosed and pharmacologically-treated type 1 and type 2 diabetes (fasting blood&#xD;
             glucose ≥ 7 mmol/l)&#xD;
&#xD;
          2. Use of medication/supplements for blood glucose control&#xD;
&#xD;
          3. Pharmacologically-treated (medication/supplements) hypertension or dyslipidemia&#xD;
&#xD;
          4. Cardiovascular disease, hypertensive retinopathy, left ventricular dysfunction,&#xD;
             secondary hypertension, liver dysfunction/disease, kidney dysfunction/disease,&#xD;
             dementia, thyroid disease, pancreatic disease, history of cancer within past 5 years&#xD;
             (excluding basal cell carcinoma), anemia, or any other disease or condition which, in&#xD;
             the Investigator's opinion, could interfere with the results of the study or the&#xD;
             safety of the subject&#xD;
&#xD;
          5. Use of drugs or supplements to manage body weight or body fat in the last 3 months&#xD;
&#xD;
          6. Use of laxatives or fiber supplements in the past 6 weeks.&#xD;
&#xD;
          7. History of chronic active inflammatory disorders&#xD;
&#xD;
          8. History of bariatric surgery&#xD;
&#xD;
          9. History of any chronic gastrointestinal disease (e.g. IBD) or disorders (e.g. IBS,&#xD;
             constipation, diarrhea), or gastrointestinal reflux disease&#xD;
&#xD;
         10. Regular use of non-steroidal anti-inflammatory drugs, systemic or inhaled&#xD;
             corticosteroids, or systemic immunomodulatory drugs&#xD;
&#xD;
         11. Regular (more than once per week) use of proton pump inhibitors&#xD;
&#xD;
         12. Recent (last 3 months) or ongoing antibiotic use&#xD;
&#xD;
         13. Immunosuppression or ongoing therapy causing immunosuppression&#xD;
&#xD;
         14. Use of probiotic supplements during the previous 6 weeks&#xD;
&#xD;
         15. Significant change in tobacco, snuff, nicotine and e-cigarette use habits in the past&#xD;
             3 months or planned cessation of the use of these products during the trial&#xD;
&#xD;
         16. Use of vitamin D supplementation of ≥100 µg/day&#xD;
&#xD;
         17. Active or recent (last 3 months) participation in a weight loss program (diet and/or&#xD;
             exercise)&#xD;
&#xD;
         18. Weight change (increase or loss) of 3 kg during the past 3 months&#xD;
&#xD;
         19. Pregnant or planning pregnancy during the study or breastfeeding&#xD;
&#xD;
         20. Participation in a clinical trial with an investigational product or drug within 60&#xD;
             days prior to screening&#xD;
&#xD;
         21. Likeliness to be noncompliant with the protocol&#xD;
&#xD;
         22. No possibility of contact in case of emergency&#xD;
&#xD;
         23. Illicit drug users&#xD;
&#xD;
         24. Alcohol abusers&#xD;
&#xD;
         25. Administrative or legal supervision&#xD;
&#xD;
         26. Subject who would receive more than 4500 euros as indemnities for his participation in&#xD;
             biomedical research within the 12 last months, including the indemnities for the&#xD;
             present study&#xD;
&#xD;
         27. Other reasons that, in the opinion of the Investigator, make the participant&#xD;
             unsuitable for enrolment&#xD;
&#xD;
         28. Other reasons that, in the opinion of the Investigator, make the participant&#xD;
             unsuitable for enrolment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CEN nutriment</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie Cacace</last_name>
      <phone>+334 38 37 25 67</phone>
      <email>SophieCacace@eurofins.com</email>
    </contact>
    <contact_backup>
      <last_name>Pauline Leveille</last_name>
      <phone>+334 38 37 25 61</phone>
      <email>PaulineLEVEILLE@eurofins.com</email>
    </contact_backup>
    <investigator>
      <last_name>Nadège Plaza, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Esther Milojevitch, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Eurofins Optimed</name>
      <address>
        <city>Gières</city>
        <zip>38610</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie Cacace</last_name>
      <phone>+334 38 37 25 67</phone>
      <email>SophieCacace@eurofins.com</email>
    </contact>
    <contact_backup>
      <last_name>Pauline Leveille</last_name>
      <phone>+ 33 438 37 25 61</phone>
      <email>PaulineLEVEILLE@eurofins.com</email>
    </contact_backup>
    <investigator>
      <last_name>Yves Donazzolo, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mathilde Latreille Barbier, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Valentina Hodaj, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Biofortis SAS</name>
      <address>
        <city>Saint-Herblain</city>
        <zip>44800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie Cacace</last_name>
      <phone>+334 38 37 25 67</phone>
      <email>SophieCacace@eurofins.com</email>
    </contact>
    <contact_backup>
      <last_name>Pauline Leveille</last_name>
      <phone>+334 38 37 25 61</phone>
      <email>PaulineLEVEILLE@eurofins.com</email>
    </contact_backup>
    <investigator>
      <last_name>Isabelle Metreau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie Deciron, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cap Vallcarca</name>
      <address>
        <city>Barcelona</city>
        <zip>08023</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silvia Crespo</last_name>
      <phone>+34 930 16 01 26</phone>
      <email>screspo@syntaxfs.com</email>
    </contact>
    <contact_backup>
      <last_name>Marta Rafart</last_name>
      <phone>+34 930 16 01 26</phone>
      <email>mrafart@syntaxfs.com</email>
    </contact_backup>
    <investigator>
      <last_name>Alexis Tena Domingo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CAP Centelles</name>
      <address>
        <city>Barcelona</city>
        <zip>8540</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silvia Crespo</last_name>
      <phone>+34 930 16 01</phone>
      <email>screspo@syntaxfs.com</email>
    </contact>
    <contact_backup>
      <last_name>Marta Rafart</last_name>
      <phone>+34 930 16 01 26</phone>
      <email>mrafart@syntaxfs.com</email>
    </contact_backup>
    <investigator>
      <last_name>Xavier Farres, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Helena Ferrer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CAP Hostalets</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silvia Crespo</last_name>
      <phone>+34 930 16 01 26</phone>
      <email>screspo@syntaxfs.com</email>
    </contact>
    <contact_backup>
      <last_name>Marta Rafart</last_name>
      <phone>+34 930 16 01 26</phone>
      <email>mrafart@syntaxfs.com</email>
    </contact_backup>
    <investigator>
      <last_name>Xavier Farres, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Helena Ferrer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CAP Perelada</name>
      <address>
        <city>Girona</city>
        <zip>17491</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>CAP Muralles</name>
      <address>
        <city>Tarragona</city>
        <zip>43002</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silvia Crespo</last_name>
      <phone>+34 930 16 01 26</phone>
      <email>screspo@syntaxfs.com</email>
    </contact>
    <contact_backup>
      <last_name>Marta Rafart</last_name>
      <phone>+34 930 16 01 26</phone>
      <email>mrafart@syntaxfs.com</email>
    </contact_backup>
    <investigator>
      <last_name>Cristina Picazo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>April 18, 2019</study_first_submitted>
  <study_first_submitted_qc>April 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 1, 2019</study_first_posted>
  <last_update_submitted>August 28, 2020</last_update_submitted>
  <last_update_submitted_qc>August 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Overweight</keyword>
  <keyword>Obesity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

